Home/Stacks/Immune Resilience Stack
IMMUNE STACK

Immune Resilience Stack

Thymosin Alpha-1 + KPV + LL-37 — the immune-modulating combination users research for chronic low-grade inflammation.

Educational overview only — not medical advice. No compound in this stack is presented as a treatment for any condition. Any protocol decision is a conversation with your licensed healthcare provider.

About This Stack

The Immune Resilience Stack combines three peptides with immune-modulating mechanisms: Thymosin Alpha-1 (T-cell maturation signal), KPV (tripeptide with anti-inflammatory activity), and LL-37 (cathelicidin-class antimicrobial peptide). Each operates on a different immune axis, which is why they are commonly discussed together.

Users research this combination in the context of chronic low-grade inflammation, slow-to-heal infections, or gut-immune concerns. The compounds are all research-only in the US and require careful sourcing — quality and authenticity vary substantially in the gray market.

None of these compounds is presented as a treatment for any infection or autoimmune condition. Clinical immune dysfunction requires licensed medical evaluation.

Why These Compounds Are Researched Together

Thymosin Alpha-1 drives T-cell maturation and is approved in some countries for specific immune indications. KPV is the C-terminal tripeptide of alpha-MSH with documented anti-inflammatory effects on gut epithelium. LL-37 is the active form of cathelicidin (broad antimicrobial + immunomodulatory). The three mechanisms — T-cell signaling, epithelial anti-inflammation, antimicrobial activity — are distinct and complementary.

Compounds in the Immune Resilience Stack

Thymosin Alpha-1T-CELL SIGNAL
Thymosin Alpha-1 (Tα1)
Thymic peptide that drives T-cell maturation and function.
kpvANTI-INFLAMMATORY
Alpha-MSH-derived tripeptide with documented anti-inflammatory activity.
ll-37ANTIMICROBIAL
Cathelicidin-class peptide with broad antimicrobial + immunomodulatory research.

Biomarkers Users Commonly Track

When running a stack like this, these biomarkers let users see how the compounds perform in context. Trended across draws, they reveal whether the stack is actually moving the markers it should — or producing unintended shifts that warrant a provider conversation.

INFLAMMATION
hs-CRP
Primary marker of systemic inflammation.
HEMATOLOGY
WBC
Total immune-cell count — baseline before any immune-modulating compound.
INFLAMMATION
IL-6
Upstream inflammation cytokine — more sensitive than hs-CRP in some contexts.
NUTRIENT
Ferritin
Acute-phase reactant — elevated in chronic low-grade inflammation.

Typical Cycle

Thymosin Alpha-1 cycles commonly run 3–6 months in community reports. KPV and LL-37 cycles vary by goal. All cycling decisions are a conversation with a licensed provider.

What to Discuss With Your Provider

Chronic inflammation has many causes (infection, autoimmunity, dental, sleep apnea). A workup with a licensed provider should precede any immune-modulating peptide research.

Related Stacks

LONGEVITY
Longevity Core Stack
Epithalon + BPC-157 + GHK-Cu — the foundational long-cycle combination users research for cellular aging and systemic repair.
Track the Immune Resilience Stack against your labs.

Log every compound in the stack, upload your lab PDFs, and chart the biomarkers on this page across every draw. StackAI reads the panel in context of what you’re running.

Start tracking free →
Compliance notice: This page is informational and educational only. MyProtocolStack does not provide medical advice, diagnosis, or treatment. All references to compounds describe what users research and typically discuss with their clinician — not endorsements, prescriptions, or treatment recommendations. Research-stage compounds discussed are not FDA-approved unless specifically noted. Any protocol decision requires a licensed healthcare provider.